Marker Therapeutics Inc. [MRKR] stock Initiated by Piper Sandler analyst, price target now $6

Marker Therapeutics Inc. [NASDAQ: MRKR] gained 31.50% on the last trading session, reaching $0.40 price per share at the time. The company report on September 8, 2022 that Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Peter L. Hoang, Marker’s President and Chief Executive Officer, will participate in a panel discussion titled, “CAR-T and Beyond: What Are the Next Generation Cell Therapies?,” at the Cantor Fitzgerald Cell and Genetic Medicines Conference in New York on Thursday, September 15, 2022 at 9:20 a.m. ET.

Those interested in participating in the conference are encouraged to contact their Cantor Fitzgerald representative.

Marker Therapeutics Inc. represents 83.59 million in outstanding shares, while the company has a total market value of $33.56 million with the latest information. MRKR stock price has been found in the range of $0.30 to $0.48.

If compared to the average trading volume of 1.78M shares, MRKR reached a trading volume of 10545298 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Marker Therapeutics Inc. [MRKR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRKR shares is $2.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRKR stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Marker Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 25, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on March 19, 2021, representing the official price target for Marker Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Piper Sandler kept a Neutral rating on MRKR stock.

The Average True Range (ATR) for Marker Therapeutics Inc. is set at 0.05, with the Price to Sales ratio for MRKR stock in the period of the last 12 months amounting to 11.19. The Price to Book ratio for the last quarter was 1.18, with the Price to Cash per share for the same quarter was set at 0.31.

Trading performance analysis for MRKR stock

Marker Therapeutics Inc. [MRKR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.00. With this latest performance, MRKR shares dropped by -21.97% in over the last four-week period, additionally sinking by -16.69% over the last 6 months – not to mention a drop of -79.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRKR stock in for the last two-week period is set at 60.58, with the RSI for the last a single of trading hit 68.70, and the three-weeks RSI is set at 57.05 for Marker Therapeutics Inc. [MRKR]. The present Moving Average for the last 50 days of trading for this stock 0.3550, while it was recorded at 0.3237 for the last single week of trading, and 0.5170 for the last 200 days.

Marker Therapeutics Inc. [MRKR]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Marker Therapeutics Inc. [MRKR] shares currently have an operating margin of -3179.32 and a Gross Margin at -154.70. Marker Therapeutics Inc.’s Net Margin is presently recorded at -3372.68.

Return on Equity for this stock declined to -117.42, with Return on Assets sitting at -73.63.

Marker Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.

An analysis of insider ownership at Marker Therapeutics Inc. [MRKR]

There are presently around $9 million, or 27.20% of MRKR stock, in the hands of institutional investors. The top three institutional holders of MRKR stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 10,714,285, which is approximately 0% of the company’s market cap and around 3.90% of the total institutional ownership; AISLING CAPITAL MANAGEMENT LP, holding 3,142,857 shares of the stock with an approximate value of $1.26 million in MRKR stocks shares; and LONG FOCUS CAPITAL MANAGEMENT, LLC, currently with $0.97 million in MRKR stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Marker Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in Marker Therapeutics Inc. [NASDAQ:MRKR] by around 808,922 shares. Additionally, 24 investors decreased positions by around 1,467,304 shares, while 25 investors held positions by with 20,416,955 shares. The mentioned changes placed institutional holdings at 22,693,181 shares, according to the latest SEC report filing. MRKR stock had 5 new institutional investments in for a total of 669,984 shares, while 9 institutional investors sold positions of 632,908 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here